By Jamil Alkhaddo, MD · North County Endocrinology Associates ·
The short answer: not necessarily, but stopping is a decision to make with your doctor, slowly and on purpose, never on your own all at once.
"Do I have to take this forever?" is one of the questions I hear most from patients on medications like Wegovy (semaglutide) and Zepbound (tirzepatide). It's a fair question. These medications can be expensive, they take commitment, and most people would rather not depend on a weekly injection for life.
Here is what the science tells us, what it doesn't tell us yet, and how I help patients think about the long term.
Obesity is a chronic disease, not a willpower problem
Obesity is a chronic, relapsing disease, much like high blood pressure, high cholesterol or type 2 diabetes. For most people, managing it is a lifelong process.
One reason is that your body actively defends its highest weight. After weight loss, the hunger hormone ghrelin rises, the fullness hormones that tell your brain "I've had enough" fall, and appetite increases. In a well-known study, these changes were still present a full year after people lost weight [1]. That isn't a lack of discipline. It's biology pushing you back toward where you started.
This is why weight regain after any kind of weight loss is so common, and why we think about long-term treatment rather than a quick fix.
What happens when people stop?
In the large studies, most people regained a meaningful amount of weight after stopping. But it matters how they stopped: in these trials, people went from a full dose straight to nothing.
Semaglutide (Wegovy), STEP 1: People lost an average of about 17% of their body weight over 68 weeks. One year after stopping the medication (and the lifestyle program), they had regained about two-thirds of what they lost [2].
Semaglutide, STEP 4: After 20 weeks on the medication, people who switched to a placebo (an inactive shot) regained about 7% of their body weight over the next 48 weeks. Those who stayed on semaglutide kept losing [3].
Tirzepatide (Zepbound), SURMOUNT-4: After about 21% weight loss in 36 weeks, people switched to placebo regained 14% of their body weight over the following year. Those who continued lost a further 5.5% [4].
All medications combined: A 2026 review of 37 studies found that after stopping, weight came back at about 0.4 kg (roughly 1 pound) per month on average. That pace would bring most people back to their starting weight in about 1.7 years [5].
Regain also brought back health problems. Blood pressure, cholesterol and blood sugar improvements tended to fade as the weight returned [2, 5].
The key point: nearly all of this research tested an abrupt stop. These studies were not designed to test a slow, supervised taper. That is a different question, and one we are only starting to answer.
Not everyone regains the weight
Even after an abrupt stop, some people kept most of their weight off. In the tirzepatide study, about 1 in 6 people (54 of 308) regained less than a quarter of the weight they had lost a year after stopping. Their waist size, blood pressure and other health markers stayed largely improved [6].
We don't yet know exactly what those people did differently. That is one of the most important open questions in obesity medicine, and more research is needed.
We do know a lot about what helps people keep weight off in general. People in the National Weight Control Registry, who have lost an average of over 70 pounds and kept it off for more than 5 years, share a few habits [7]:
Regular physical activity, about an hour a day for many of them
Watching calories, often by tracking or counting what they eat
Weighing themselves regularly, so small gains get caught early
Eating consistently, with a similar pattern on weekdays and weekends
The encouraging part: keeping weight off seems to get easier with time. People who maintained their loss for 2 to 5 years had a much better chance of long-term success [7].
Give your body time at its new weight
These are powerful medications. Many patients lose 15–20% of their body weight within about a year to a year and a half, which is far faster than most people could manage with diet and exercise alone.
Your body hasn't caught up with that change yet. The hormonal push toward regain can last at least a year after weight loss [1], and the habits that protect your results take time to become automatic.
That's why I usually recommend a maintenance period at your new, stable weight before we talk about lowering the dose. There isn't yet a study that defines the ideal length of that period, so this is clinical judgment rather than a fixed rule. During maintenance, the goal is to build and practice the habits above while the medication is still helping you.
Stepping down slowly, with your doctor
New research suggests there is a middle ground between full-dose treatment forever and stopping cold turkey.
Lower-dose maintenance works for many people. In a 2026 study, people who lost weight on full-dose tirzepatide were then assigned to stay on full dose, step down to the lowest standard dose (5 mg), or stop. After more than two years, the full-dose group was down about 22% from their starting weight, the lower-dose group about 17%, and the group that stopped about 10% [8]. Only 25% of the lower-dose group regained half or more of their lost weight, compared with 67% of those who stopped [8].
Gradual tapering looks promising. In a small real-world study from Denmark, people who slowly tapered semaglutide to zero over about 9 weeks, while getting diet and exercise coaching, kept a stable weight for at least 6 months after their last dose [9]. This was early data presented at a medical conference, not yet a full randomized trial, but it fits what many of us see in practice. Larger tapering trials are now underway.
In my practice, I have worked with many patients to lower their dose slowly, step by step, until they are on a very low dose or off the medication entirely. We make each change only when weight is stable, check in regularly, and keep a plan in place: if weight starts creeping back up, we can go back up a step. Needing to stay on a medication, or restarting one, is not a failure. It is treating a chronic disease.
Please don't stop or lower your dose on your own. This is especially important if you take Ozempic or Mounjaro for type 2 diabetes, since stopping can raise your blood sugar.
The bottom line
You may not need these medications forever, but for most people, managing weight is a lifelong commitment, with or without medication.
Obesity is a chronic disease, and your body works hard to regain lost weight.
Stopping suddenly usually leads to significant regain, but some people do keep their weight off.
Exercise, watching calories and regular weigh-ins are the habits most linked to long-term success.
A stable maintenance period, followed by a slow, supervised step-down, gives you the best chance of keeping your results.
Make any change to your dose with your clinician, never on your own.
If you're wondering whether it's time to lower your dose, or you'd like help building a long-term plan, I'd be glad to talk it through. You can reach North County Endocrinology Associates at ncendocrinology.com.
References
Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597-1604.
Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564.
Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425.
Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38-48.
West S, Scragg J, Aveyard P, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ. 2026;392:e085304.
Horn DB, Linetzky B, Davies MJ, et al. Cardiometabolic parameter change by weight regain on tirzepatide withdrawal in adults with obesity: a post hoc analysis of the SURMOUNT-4 trial. JAMA Intern Med. 2026. doi:10.1001/jamainternmed.2025.6112
Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr. 2005;82(1 Suppl):222S-225S.
Horn DB, Aronne LJ, Wharton S, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2026;407:2305-2318.
European Association for the Study of Obesity. Is coming off semaglutide slowly the key to preventing weight regain? (Gudbergsen H, lead researcher). News release on data presented at the European Congress on Obesity; May 2024; Venice, Italy.